Traditionally, New Year’s resolutions to lose weight involve getting to the gym more. In a post-GLP-1 world, that’s looking less necessary.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
A new study suggests increasingly popular GLP-1 drugs could help cut opioid and alcohol abuse nearly in half.
New estimates say that Medicare will spend tens of billions of dollars over nine years to cover weight-loss drugs.
Obesity drugmaker Rivus is working with banks to complete a US public listing that could happen before the end of the year.
The toast of Wall Street has elevated a new generation of executives to run its investment banking and trading operations.
Mistral is among a clutch of privately held AI startups like OpenAI and Anthropic that have seen valuations soar.
The Trump 2.0 era may have officially begun this week, but the much-hyped tariff-fueled trade war has not. At least, not yet.